Trial Profile

An Open-Label, Non-randomized, Multi-center Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Bi-Ligand-Drug Conjugate CBP-1018 in Patients With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 30 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CBP 1018 (Primary)
Indications Bladder cancer; Carcinoma; Lung cancer; Prostate cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer; Ureteral neoplasms
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Coherent Biopharma (Suzhou)

16 Jun 2026 According to a MultiValent Biotherapies media release, company expects to initiate this trial in US in the third quarter of 2026.
16 Jun 2026 According to a MultiValent Biotherapies media release, company announced the first closing of $27 million Series A financing and this funding will support this trial.
28 Aug 2024 Planned End Date changed from 1 Oct 2024 to 1 Dec 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com